514 related articles for article (PubMed ID: 19039815)
21. A three-dimensional in silico pharmacophore model for inhibition of Plasmodium falciparum cyclin-dependent kinases and discovery of different classes of novel Pfmrk specific inhibitors.
Bhattacharjee AK; Geyer JA; Woodard CL; Kathcart AK; Nichols DA; Prigge ST; Li Z; Mott BT; Waters NC
J Med Chem; 2004 Oct; 47(22):5418-26. PubMed ID: 15481979
[TBL] [Abstract][Full Text] [Related]
22. [Development of new antitumor reagents which block the cell cycle progression].
Osada H
Gan To Kagaku Ryoho; 1997 Sep; 24(11):1541-6. PubMed ID: 9309153
[TBL] [Abstract][Full Text] [Related]
23. Small molecules as inhibitors of cyclin-dependent kinases.
Huwe A; Mazitschek R; Giannis A
Angew Chem Int Ed Engl; 2003 May; 42(19):2122-38. PubMed ID: 12761741
[TBL] [Abstract][Full Text] [Related]
24. CDKs and CKIs: molecular targets for tissue remodelling.
Nabel EG
Nat Rev Drug Discov; 2002 Aug; 1(8):587-98. PubMed ID: 12402499
[TBL] [Abstract][Full Text] [Related]
25. Cip/Kip cyclin-dependent kinase inhibitors: brakes of the cell cycle engine during development.
Nakayama K; Nakayama K
Bioessays; 1998 Dec; 20(12):1020-9. PubMed ID: 10048302
[TBL] [Abstract][Full Text] [Related]
26. Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs.
Roskoski R
Pharmacol Res; 2019 Jan; 139():471-488. PubMed ID: 30508677
[TBL] [Abstract][Full Text] [Related]
27. CDK inhibitors in cancer therapy: what is next?
Malumbres M; Pevarello P; Barbacid M; Bischoff JR
Trends Pharmacol Sci; 2008 Jan; 29(1):16-21. PubMed ID: 18054800
[TBL] [Abstract][Full Text] [Related]
28. [Prevention of chemotherapy-induced alopecia by cyclin-dependant kinase inhibitors].
Meijer L; Knockaert M; Damiens E
Bull Cancer; 2001 Apr; 88(4):347-50. PubMed ID: 11371368
[TBL] [Abstract][Full Text] [Related]
29. Peptides or small molecules? Different approaches to develop more effective CDK inhibitors.
Cirillo D; Pentimalli F; Giordano A
Curr Med Chem; 2011; 18(19):2854-66. PubMed ID: 21651493
[TBL] [Abstract][Full Text] [Related]
30. High-resolution crystal structures of human cyclin-dependent kinase 2 with and without ATP: bound waters and natural ligand as guides for inhibitor design.
Schulze-Gahmen U; De Bondt HL; Kim SH
J Med Chem; 1996 Nov; 39(23):4540-6. PubMed ID: 8917641
[TBL] [Abstract][Full Text] [Related]
31. Fluorescent cyclin-dependent kinase inhibitors block the proliferation of human breast cancer cells.
Yenugonda VM; Deb TB; Grindrod SC; Dakshanamurthy S; Yang Y; Paige M; Brown ML
Bioorg Med Chem; 2011 Apr; 19(8):2714-25. PubMed ID: 21440449
[TBL] [Abstract][Full Text] [Related]
32. Anticancer therapeutic strategies based on CDK inhibitors.
Esposito L; Indovina P; Magnotti F; Conti D; Giordano A
Curr Pharm Des; 2013; 19(30):5327-32. PubMed ID: 23394082
[TBL] [Abstract][Full Text] [Related]
33. Discovery of cyclin-dependent kinase inhibitor, CR229, using structurebased drug screening.
Kim MK; Min J; Choi BY; Lim H; Cho YH; Lee CH
J Microbiol Biotechnol; 2007 Oct; 17(10):1712-6. PubMed ID: 18156791
[TBL] [Abstract][Full Text] [Related]
34. Structure and inhibitor specificity of the PCTAIRE-family kinase CDK16.
Dixon-Clarke SE; Shehata SN; Krojer T; Sharpe TD; von Delft F; Sakamoto K; Bullock AN
Biochem J; 2017 Feb; 474(5):699-713. PubMed ID: 28057719
[TBL] [Abstract][Full Text] [Related]
35. Anticancer activity and differentially expressed genes in head and neck cancer cells treated with a novel cyclin-dependent kinase inhibitor.
Shin HC; Song DW; Baek WK; Lee SR; Kwon TK; Lee J; Park SH; Jang BC; Park JW
Chemotherapy; 2009; 55(5):353-62. PubMed ID: 19657189
[TBL] [Abstract][Full Text] [Related]
36. CDK/GSK-3 inhibitors as a new approach for the treatment of proliferative renal diseases.
Soos TJ; Meijer L; Nelson PJ
Drug News Perspect; 2006; 19(6):325-8. PubMed ID: 16971968
[TBL] [Abstract][Full Text] [Related]
37. Fluorescent biosensors for drug discovery new tools for old targets--screening for inhibitors of cyclin-dependent kinases.
Prével C; Kurzawa L; Van TN; Morris MC
Eur J Med Chem; 2014 Dec; 88():74-88. PubMed ID: 25314935
[TBL] [Abstract][Full Text] [Related]
38. Structural insights of cyclin dependent kinases: Implications in design of selective inhibitors.
Kalra S; Joshi G; Munshi A; Kumar R
Eur J Med Chem; 2017 Dec; 142():424-458. PubMed ID: 28911822
[TBL] [Abstract][Full Text] [Related]
39. Cyclin-dependent kinase modulators: a novel class of cell cycle regulators for cancer therapy.
Senderowicz AM
Cancer Chemother Biol Response Modif; 2001; 19():165-88. PubMed ID: 11686013
[TBL] [Abstract][Full Text] [Related]
40. Mechanistic insights into avian reovirus p17-modulated suppression of cell cycle CDK-cyclin complexes and enhancement of p53 and cyclin H interaction.
Chiu HC; Huang WR; Liao TL; Chi PI; Nielsen BL; Liu JH; Liu HJ
J Biol Chem; 2018 Aug; 293(32):12542-12562. PubMed ID: 29907572
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
